Capabilities by Region: Canada
Greenhill has considerable advisory experience in Canada. Our Managing Directors and professionals have advised clients on transactions involving many of the leading companies in the region and have access to a vast network of corporate relationships throughout Canada.
Greenhill established its presence in Canada in June 2006 with the acquisition of Toronto-based Beaufort Partners.
For more information on Greenhill’s advisory practice in Canada and our capabilities in the region, please contact Managing Director Steve Mayer in our Toronto office.
Below we highlight a few of the transactions on which we have advised in this region:
Recent Transactions
Sort By
US rights to Toprol-XL (AstraZeneca)
Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.
Whistler Blackcomb Holdings Inc.
Advised Whistler Blackcomb Holdings Inc., a 75% owner and operator of the largest and most visited mountain resort in North America, on its sale to Vail Resorts, Inc.
Aegerion Pharmaceuticals
Advised QLT Inc. on its merger with Aegerion Pharmaceuticals and concurrent equity raise to create a rare disease-focused global biopharmaceutical organization
Niska Gas Storage Partners
Advised the Conflicts Committee of the Board of Directors of Niska and provided a fairness opinion on its sale to Brookfield
Aralez Pharmaceuticals Inc.
Advised QLT Inc. on its strategic equity investment in Aralez Pharmaceuticals Inc., a newly formed global specialty pharmaceutical company resulting from the business combination of POZEN Inc. and Tribute Pharmaceuticals Canada Inc., and the special distribution of the Aralez shares to QLT shareholders.